Our MDL-207 approach to Dravet Syndrome was featured in BioCentury.

In an article covering the efforts of various companies to develop a treatment for Dravet Syndrome, MDL-207, which MODALIS is developing, is mentioned as one of the promising candidates in the following article (paid subscription required).

2025.3.1 BioCentury titled “Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline”